Home » Stocks » PPBT

Purple Biotech Ltd. (PPBT)

Stock Price: $3.75 USD -0.13 (-3.35%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $3.80 +0.05 (1.33%) May 12, 7:29 PM
Market Cap 66.36M
Revenue (ttm) 1,000,000
Net Income (ttm) 28.00M
Shares Out 17.51M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $3.75
Previous Close $3.88
Change ($) -0.13
Change (%) -3.35%
Day's Open 3.85
Day's Range 3.70 - 3.95
Day's Volume 248,248
52-Week Range 0.41 - 7.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Preliminary Data from First Part of Study Anticipated in Second Half of 2021

2 weeks ago - GlobeNewsWire

TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...

4 weeks ago - GlobeNewsWire

Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb

1 month ago - GlobeNewsWire

TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...

2 months ago - GlobeNewsWire

Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by ov...

2 months ago - GlobeNewsWire

Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple Bio...

Other stocks mentioned: PRPL
3 months ago - InvestorPlace

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio...

Other stocks mentioned: KTOV
3 months ago - GlobeNewsWire

Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech

4 months ago - GlobeNewsWire

New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies

Other stocks mentioned: KTOV
5 months ago - GlobeNewsWire

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug...

Other stocks mentioned: KTOV
6 months ago - GlobeNewsWire

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explore the com...

Other stocks mentioned: KTOV
6 months ago - GlobeNewsWire

Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)

Other stocks mentioned: KTOV
6 months ago - GlobeNewsWire

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

Other stocks mentioned: KTOV
6 months ago - GlobeNewsWire

Top Line Results from First Part of the Study Expected in Second Half of 2021 Top Line Results from First Part of the Study Expected in Second Half of 2021

Other stocks mentioned: KTOV
8 months ago - GlobeNewsWire

Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries

Other stocks mentioned: KTOV
8 months ago - GlobeNewsWire

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
9 months ago - GlobeNewsWire

TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
9 months ago - GlobeNewsWire

Is (KTOV) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: KTOV
9 months ago - Zacks Investment Research

Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer

Other stocks mentioned: KTOV
10 months ago - GlobeNewsWire

Patent coverage for CM24 now extends to the U.S. and the EU

Other stocks mentioned: KTOV
10 months ago - GlobeNewsWire

Ties With Merck Could Explain Kitov's Market Interest

Other stocks mentioned: KTOV
10 months ago - Seeking Alpha

TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resista...

Other stocks mentioned: KTOV
10 months ago - GlobeNewsWire

TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
10 months ago - GlobeNewsWire

TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
10 months ago - GlobeNewsWire

Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase 1/...

Other stocks mentioned: KTOV
11 months ago - GlobeNewsWire

TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
11 months ago - GlobeNewsWire

Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head a...

Other stocks mentioned: KTOV
11 months ago - GlobeNewsWire

Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020

Other stocks mentioned: KTOV
11 months ago - GlobeNewsWire

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
11 months ago - Seeking Alpha

TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dru...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced it will expand the plan...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Tufin Software Technologies' (TUFN) CEO Ruvi Kitov on Q4 2019 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
1 year ago - Seeking Alpha

Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and d...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Kitov Pharma recently updated their Consensi commercial agreement with Coeptis Pharmaceuticals. I review the original and updated agreement and provide my thoughts on the amendments.

Other stocks mentioned: KTOV
1 year ago - Seeking Alpha

TEL AVIV, Israel, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Kitov Pharma presented encouraging NT-219 data that confirmed its mechanism of action in reversing drug resistance in mouse models. The company is planning on submitting an IND before year-end.

Other stocks mentioned: KTOV
1 year ago - Seeking Alpha

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, presented newly released proof-of-conce...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q2 2019 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
1 year ago - Seeking Alpha

TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and d...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...

Other stocks mentioned: KTOV
1 year ago - GlobeNewsWire

Kitov Pharma's Consensi is close to launching and will mark the company's transition into a commercial-stage company. However, the stock trades under $1 and is at risk for delisting.

Other stocks mentioned: KTOV
1 year ago - Seeking Alpha

Kitov is in the final stages of acquiring FameWave and their promising oncology agent CM-24. This acquisition now makes a Kitov an oncology-focused company.

Other stocks mentioned: KTOV
2 years ago - Seeking Alpha

About PPBT

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and ... [Read more...]

Industry
Biotechnology
Founded
2010
CEO
Itzhak Israel
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
PPBT
Full Company Profile

Financial Performance

In 2020, Purple Biotech's revenue was $1,000,000, a change of 0.00% compared to the previous year's $1,000,000. Earnings were $28.00 million, an increase of 378.62%.

Financial Statements